vs
Side-by-side financial comparison of FIRST FINANCIAL CORP (THFF) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $70.5M, roughly 1.8× FIRST FINANCIAL CORP). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 14.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 20.8%).
First American Financial Corporation is an American financial services company which provides title insurance and settlement services to the real estate and mortgage industries.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
THFF vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $70.5M | $129.7M |
| Net Profit | $21.5M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 37.4% | -25.0% |
| Net Margin | 30.4% | — |
| Revenue YoY | 14.1% | 73.4% |
| Net Profit YoY | 32.1% | — |
| EPS (diluted) | $1.81 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $70.5M | $129.7M | ||
| Q3 25 | $65.8M | $164.9M | ||
| Q2 25 | $63.1M | $114.4M | ||
| Q1 25 | $62.5M | $81.7M | ||
| Q4 24 | $61.8M | $74.8M | ||
| Q3 24 | $58.4M | $62.9M | ||
| Q2 24 | $49.2M | $54.1M | ||
| Q1 24 | $48.4M | $41.4M |
| Q4 25 | $21.5M | — | ||
| Q3 25 | $20.8M | $25.7M | ||
| Q2 25 | $18.6M | $-12.8M | ||
| Q1 25 | $18.4M | $-41.2M | ||
| Q4 24 | $16.2M | — | ||
| Q3 24 | $8.7M | $-54.8M | ||
| Q2 24 | $11.4M | $-70.4M | ||
| Q1 24 | $10.9M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | 37.4% | -25.0% | ||
| Q3 25 | 39.2% | 15.1% | ||
| Q2 25 | 36.2% | -11.1% | ||
| Q1 25 | 38.1% | -52.2% | ||
| Q4 24 | 32.4% | -81.2% | ||
| Q3 24 | 17.9% | -89.3% | ||
| Q2 24 | 27.6% | -125.1% | ||
| Q1 24 | 27.2% | -336.5% |
| Q4 25 | 30.4% | — | ||
| Q3 25 | 31.6% | 15.6% | ||
| Q2 25 | 29.5% | -11.1% | ||
| Q1 25 | 29.5% | -50.4% | ||
| Q4 24 | 26.3% | — | ||
| Q3 24 | 15.0% | -87.1% | ||
| Q2 24 | 23.1% | -130.1% | ||
| Q1 24 | 22.6% | -328.9% |
| Q4 25 | $1.81 | $0.04 | ||
| Q3 25 | $1.75 | $0.28 | ||
| Q2 25 | $1.57 | $-0.14 | ||
| Q1 25 | $1.55 | $-0.47 | ||
| Q4 24 | $1.37 | $-0.71 | ||
| Q3 24 | $0.74 | $-0.70 | ||
| Q2 24 | $0.96 | $-0.91 | ||
| Q1 24 | $0.93 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $93.0M |
| Total DebtLower is stronger | $188.2M | — |
| Stockholders' EquityBook value | $650.9M | $114.8M |
| Total Assets | $5.8B | $605.2M |
| Debt / EquityLower = less leverage | 0.29× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | — | $75.2M | ||
| Q1 25 | — | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $32.3M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | $188.2M | — | ||
| Q3 25 | $170.5M | — | ||
| Q2 25 | $122.7M | — | ||
| Q1 25 | $124.9M | — | ||
| Q4 24 | $28.1M | — | ||
| Q3 24 | $30.5M | — | ||
| Q2 24 | $108.6M | — | ||
| Q1 24 | $58.6M | — |
| Q4 25 | $650.9M | $114.8M | ||
| Q3 25 | $622.2M | $73.6M | ||
| Q2 25 | $587.7M | $32.7M | ||
| Q1 25 | $571.9M | $32.8M | ||
| Q4 24 | $549.0M | $59.1M | ||
| Q3 24 | $566.0M | $-30.5M | ||
| Q2 24 | $530.7M | $15.1M | ||
| Q1 24 | $520.8M | $74.1M |
| Q4 25 | $5.8B | $605.2M | ||
| Q3 25 | $5.7B | $538.6M | ||
| Q2 25 | $5.6B | $555.3M | ||
| Q1 25 | $5.5B | $548.8M | ||
| Q4 24 | $5.6B | $594.1M | ||
| Q3 24 | $5.5B | $504.4M | ||
| Q2 24 | $4.9B | $551.1M | ||
| Q1 24 | $4.9B | $663.5M |
| Q4 25 | 0.29× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 0.21× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.20× | — | ||
| Q1 24 | 0.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $90.4M | $60.7M |
| Free Cash FlowOCF − Capex | $86.4M | — |
| FCF MarginFCF / Revenue | 122.5% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | 4.21× | — |
| TTM Free Cash FlowTrailing 4 quarters | $144.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.4M | $60.7M | ||
| Q3 25 | $26.9M | $14.3M | ||
| Q2 25 | $12.7M | $5.0M | ||
| Q1 25 | $21.1M | $-42.2M | ||
| Q4 24 | $60.4M | $-35.7M | ||
| Q3 24 | $23.3M | $-42.5M | ||
| Q2 24 | $8.8M | $-40.2M | ||
| Q1 24 | $12.4M | $-119.0M |
| Q4 25 | $86.4M | — | ||
| Q3 25 | $25.8M | $14.2M | ||
| Q2 25 | $11.6M | — | ||
| Q1 25 | $20.5M | — | ||
| Q4 24 | $54.3M | — | ||
| Q3 24 | $19.5M | — | ||
| Q2 24 | $8.4M | $-40.3M | ||
| Q1 24 | $11.5M | — |
| Q4 25 | 122.5% | — | ||
| Q3 25 | 39.2% | 8.6% | ||
| Q2 25 | 18.4% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 87.8% | — | ||
| Q3 24 | 33.5% | — | ||
| Q2 24 | 17.2% | -74.5% | ||
| Q1 24 | 23.7% | — |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 1.7% | 0.1% | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 9.9% | — | ||
| Q3 24 | 6.5% | 0.0% | ||
| Q2 24 | 0.7% | 0.2% | ||
| Q1 24 | 2.0% | 0.0% |
| Q4 25 | 4.21× | — | ||
| Q3 25 | 1.29× | 0.56× | ||
| Q2 25 | 0.68× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | 3.72× | — | ||
| Q3 24 | 2.67× | — | ||
| Q2 24 | 0.77× | — | ||
| Q1 24 | 1.14× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
THFF
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
